Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial

Journal of Microbiology, Immunology and Infection

Volumn 52, Issue 1, 2019, Pages 35-44

  Yuan, Jinyi ^a,b   Mo, Biwen ^c   Ma, Zhuang ^d   Lv, Yuan ^e   Cheng, Shih Lung ^f   Yang, Yanping ^g   Tong, Zhaohui ^h   Wu, Renguang ⁱ   Sun, Shenghua ^j   Cao, Zhaolong ^k   Wu, Jufang ^a,b   Zhu, Demei ^a,b   Chang, Liwen ^l   Zhang, Yingyuan ^a,b   Zhao, Li ^m   Wang, Xiongbiao ⁿ   Wang, Xuefen ^o   Wang, Dexi ^p   Li, Xiangyang ^q   Peng, Yiqiang ^r   Liang, Yongjie ^s   Liu, Hua ^t   Xiao, Zuke ^u   Lv, Xiaoju ^v   Wu, Shiman ^w   Dai, Yuanrong ^x   Huang, Yijiang ^y   Hu, Zhenghong ^z   Qiu, Chen ^aa   Li, Xi ^ab   Zhang, Suiyang ^ac   Li, Wenpu ^ad   Liu, Shuang ^ae   Shi, Yi ^af   Xiong, Chang ^ag   Kuang, Jiulong ^ah   Xiu, Qingyu ^ai   Cui, Shehuai ^aj   Li, Jianguo ^ak   Lin, Qichang ^al   Huang, Wenxiang ^am   Wan, Yixin ^an   Qimanguli, ^ao   Shen, Ce ^ap   Xiao, Yi ^aq   Wu, Xiaoju ^ar   Chuang, Yin Ching ^as   Perng, Wann Cherng ^at   Tsao, Shih Ming ^au   Hsu, Jeng Yuan ^av   Wang, Chin Chou ^aw   Wang, Jen Hsien ^ax   Yeh, Pen Fang ^ay   Lin, His Hsun ^az   Kuo, P H ^ba   Lin, Ming Shian ^bb   Su, Wei Juin ^bc   more..

^a FUDAN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c GUILIN MEDICAL UNIVERSITY   (China)

^d GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^e PEKING UNIVERSITY FIRST HOSPITAL   (China)

^f FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^g JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^h CAPITAL MEDICAL UNIVERSITY   (China)

ⁱ CHENG CHING GENERAL HOSPITAL   (Taiwan)

^j CENTRAL SOUTH UNIVERSITY   (China)

^k PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^l TaiGen Biotechnology Co Ltd   (Taiwan)

^m CHINA MEDICAL UNIVERSITY   (China)

ⁿ Shanghai Putuo District Central Hospital   (China)

^o ZHEJIANG UNIVERSITY   (China)

^p GUANGZHOU RED CROSS HOSPITAL   (China)

^q FUDAN UNIVERSITY   (China)

^r CHANGSHA CENTRAL HOSPITAL   (China)

^s TONGJI UNIVERSITY   (China)

^t GANSU PROVINCIAL HOSPITAL   (China)

^u Jiangxi Provincial People's Hospital   (China)

^v SICHUAN UNIVERSITY   (China)

^w SHANXI MEDICAL UNIVERSITY   (China)

^x WENZHOU MEDICAL UNIVERSITY   (China)

^y HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^z WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^aa SHENZHEN PEOPLE'S HOSPITAL   (China)

^ab HAINAN MEDICAL UNIVERSITY   (China)

^ac Second Artillery General Hospital   (China)

^ad Hunan Provincial People s Hospital   (China)

^ae CAPITAL MEDICAL UNIVERSITY   (China)

^af NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

^ag HUBEI UNIVERSITY OF MEDICINE   (China)

^ah NANCHANG UNIVERSITY   (China)

^ai SECOND MILITARY MEDICAL UNIVERSITY   (China)

^aj THIRD MILITARY MEDICAL UNIVERSITY   (China)

^ak SUN YAT SEN UNIVERSITY   (China)

^al FUJIAN MEDICAL UNIVERSITY   (China)

^am THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^an LANZHOU UNIVERSITY   (China)

^ao XINJIANG MEDICAL UNIVERSITY   (China)

^ap SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^aq PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^ar RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^as CHI MEI MEDICAL CENTER   (Taiwan)

^at TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^au CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^av TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^aw CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^ax CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^ay CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^az E DA HOSPITAL   (Taiwan)

^ba NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^bb CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^bc TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

more..

Author keywords

Clinical outcome; Community acquired pneumonia; Levofloxacin; Nemonoxacin; Randomized controlled trial; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; LEVOFLOXACIN; NEMONOXACIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRADYCARDIA; CHLAMYDIA PNEUMONIAE; CLINICAL OUTCOME; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; COUGHING; CRACKLE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; HAEMOPHILUS; HEART ARREST; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; INTENTION TO TREAT ANALYSIS; KLEBSIELLA; LEGIONELLA PNEUMOPHILA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIC50; MIC90; MULTICENTER STUDY; MYCOPLASMA PNEUMONIAE; NAUSEA; NON-INFERIORITY TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; THORAX PAIN; TREATMENT DURATION; VOMITING; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMMUNITY ACQUIRED INFECTION; COMPARATIVE STUDY; DRUG EFFECT; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SAFETY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MIDDLE AGED; PNEUMONIA, BACTERIAL; QUINOLONES; SAFETY; TREATMENT OUTCOME;

EID: 85052827133     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2017.07.011     Document Type: Article

References (25)

1. Quan, T.P., Fawcett, N.J., Wrightson, J.M., et al., Infections in Oxfordshire Research Database (IORD). Increasing burden of community-acquired pneumonia leading to hospitalisation, 1998–2014. Thorax 71 (2016), 535–542.
2. Ewig, S., Birkner, N., Strauss, R., et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 64 (2009), 1062–1069.
3. Drijkoningen, J.J., Rohde, G.G., Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 20:Suppl 5 (2014), 45–51.
4. Welte, T., Torres, A., Nathwani, D., Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67 (2012), 71–79.
5. Ariza-Prota, M.A., Pando-Sandoval, A., García-Clemente, M., Fole-Vázquez, D., Casan, P., Community-acquired Moraxella catarrhalis bacteremic pneumonia: two case reports and review of the literature. Case Rep Pulmonol, 2016, 2016, 5134969.
6. Al-Aydie, S.N., Obeidat, N.M., Al-Younes, H.M., Role of Chlamydia pneumoniae in community-acquired pneumonia in hospitalized Jordanian adults. J Infect Dev Ctries 10 (2016), 227–236.
7. Dumke, R., Schnee, C., Pletz, M.W., et al. Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011–2012. Emerg Infect Dis 21 (2015), 426–434.
8. Arancibia, F., Cortes, C.P., Valdés, M., et al. Importance of Legionella pneumophila in the etiology of severe community-acquired pneumonia in Santiago, Chile. Chest 145 (2014), 290–296.
9. von Baum, H., Welte, T., Marre, R., Suttorp, N., Lück, C., Ewig, S., Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ). BMC Infect Dis, 9, 2009, 62.
10. von Baum, H., Ewig, S., Marre, R., Suttorp, N., Gonschior, S., Welte, T., Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis 46 (2008), 1356–1364.
11. Ho, P.L., Cheng, V.C., Chu, C.M., Antibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumannii. Chest 136 (2009), 1119–1127.
12. Mandell, L.A., Wunderink, R.G., Anzueto, A., et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:Suppl 2 (2007), S27–S72.
13. Chen, Y.H., Liu, C.Y., Ko, W.C., et al. Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2006–2010. Eur J Clin Microbiol Infect Dis 33 (2014), 233–239.
14. Chotikanatis, K., Kohlhoff, S.A., Hammerschlag, M.R., In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 58 (2014), 1800–1801.
15. Li, C.R., Li, Y., Li, G.Q., et al. In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. J Antimicrob Chemother 65 (2010), 2411–2415.
16. Lauderdale, T.L., Shiau, Y.R., Lai, J.F., Chen, H.C., King, C.H., Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother 54 (2010), 1338–1342.
17. Chen, Y.H., Liu, C.Y., Lu, J.J., King, C.H., Hsueh, P.R., In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother 64 (2009), 1226–1229.
18. Adam, H.J., Laing, N.M., King, C.R., Lulashnyk, B., Hoban, D.J., Zhanel, G.G., In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 53 (2009), 4915–4920.
19. Zhu, D.M., Wu, P.C., Hu, F.P., Wu, S., Ye, X.Y., Zhang, Y.Y., Activities of nemonoxacin against clinical isolates from Shanghai, China. Chin J Infect Chemother 15 (2015), 97–112.
20. Guo, B., Wu, X., Zhang, Y., et al. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Investig 32 (2012), 475–486.
21. Chung, D.T., Tsai, C.Y., Chen, S.J., et al. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother 54 (2010), 411–417.
22. Lin, L., Chang, L.W., Tsai, C.Y., et al. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother 54 (2010), 405–410.
23. Liu, Y., Zhang, Y., Wu, J., et al. A randomized, double-blind, multicenter phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia. J Microbiol Immunol Infect 50:6 (2017), 811–820.
24. van Rensburg, D.J., Perng, R.P., Mitha, I.H., et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother 54 (2010), 4098–4106.
25. Kochanek, K.D., Murphy, S.L., Xu, J., Tejada-Vera, National vital statistics reports. Deaths final data 2014. June 30, 2016 http://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65_04.pdf.